|
Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
|
|
|
|
|
|
|
Helsinn Therapeutics Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
|
|
|
HELSINN GROUP EXTENDS COLLABORATION WITH SPECIALISED THERAPEUTICS AUSTRALIA
Letter of Intent to in-license potential new therapy in the prevention of chemotherapy-induced nausea and vomiting
|
|
|
Palonosetron Better Prevents Nausea and Vomiting Linked to High Emetogenic Chemotherapy Lung Cancer Patients
New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant
|
|
|
Nimesulide: European Medicines Agency concludes positive review under Article 31 of Directive 2001/83/EC
|
|
|
HELSINN GROUP INVESTS IN THORNE RESEARCH AND WILL JOINTLY PURSUE THE DEVELOPMENT OF NUTRITIONAL PRODUCTS, INFORMATION AND SUPPORT SERVICES IN CANCER CARE
|
|
|
Helsinn and Taiho Pharmaceutical Co., Ltd. to Extend Relationship
License Agreement for Japan on Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)
|
|
|
THE HELSINN GROUP BRACES BIASCA - IL GRUPPO HELSINN PUNTA SU BIASCA
|
|
|
|
|
Helsinn Receives Scientific Advice from European Medicines Agency Supporting Phase III Trial Program of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
|
|
|
FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV
|
|
|
|